



CERTIFICATE OF LISTING OF IDENTICAL DRUG PRODUCT

Pursuant to the provisions of Republic Act (R.A.) No. 3720 as amended, known as the Foods, Drugs, Devices and Cosmetics Act, and consistent with R.A. No. 6675, known as the Generics Act of 1988, and R.A. No. 9711, otherwise known as the Food and Drug Administration Act of 2009, the product described hereunder has been found to conform with the requirements and standards for marketing authorization of pharmaceutical products per existing regulations in force as of date hereof.

Registration Number : **DRP-3087-02**

Generic Name : Co-Amoxiclav
Brand Name : Cozeal
Dosage Strength & Form : 625 mg Tablet
Pharmacologic Category : Antibacterial (Penicillin)
Classification : Prescription Drug (Rx)
Approved Shelf-life : 24 months
Storage Condition : Store at temperatures not exceeding 30°C
Packaging : Alu/Alu Blister Pack x 6's (Box of 18's)

Manufacturer : Stallion Laboratories, Pvy. Ltd
C-1B, 305/2 & 3, GIDC, Kelara (Bavla), Dist.
Ahmedabad ,Gujarat, India

Importer : Ambica International Corp.
#9 Amsterdam Extension, Merville Park Subd.,
Parañaque City

Distributor : Pharmasiv Trading
B4L11 #19 Executive Homes 1, Cainta Greenpark Vill.,
San Isidro, Cainta, Rizal


The Certificate of Listing issued to the above Distributor shall be valid until **27 June 2024**, which covers the unexpired term of the Principal CPR, subject to the conditions listed on the reverse side. No change in the ownership, registrant's address/location, manufacturer, excipients, formulation, dosage form, strength, therapeutic indication, manufacturing process, labelling and commercial presentation, and packaging of the Principal product covered by the Principal CPR without prior approval of this Office.

This Certificate of Listing is subject to suspension, cancellation or recall should any violation of R.A. No. 3720, R.A. No. 6675 and R.A. No. 9711 and/or regulations issued thereunder involving the product be committed.

Witness My Hand and Seal of this Office, this **08 October 2019**.

By Authority of the Director General
Per FDA Order No. 2016-005

K. Austria-Lock
ATTY. KATHERINE M. AUSTRIA-LOCK
Officer-in-Charge, Center for Drug Regulation and Research

REG. STATUS : Automatic Renewal
AMOUNT : Php 10,100
OR NUMBER : 1144605
DATE : 26 June 2019
BAR CODE : 
DOC TRACK : 2 0 1 9 0 3 1 1 1 3 3 4 1 6



Management
System
ISO 9001:2015
www.tuv.com
10 9102073358



FDA-0426019

Registration Number : DRP-3087-02

SPECIAL CONDITION:

Provided that nothing in the registration of the product herein granted shall be interpreted or construed as an endorsement or representation by FDA, that Registrant has the right or privilege to the use of the name or brand so registered; Registrant hereby agrees and affirms to indemnify and/or hold FDA free and harmless against any and all third-party claims on infringement of patent, trademark or intellectual property right arising from the registration of the product.

- | | | |
|---|---|---|
| X | A | This is subject to batch notification. |
| | B | This is subject to lot release certification. |
| | C | This is subject to compliance with the requirements under FDA Circular No. 2013-004 for Monitored Release (MR) drug products. |
| X | D | Subject to post-marketing surveillance of the marketing authorization holder's strict compliance to the Generic Labeling Requirements following the applicable provisions of A.O No. 2016-0008 for drug products for human use and A.O. No. 105 s. 1991 for veterinary drug products. |
| | E | Submit a satisfactory Bioequivalence Study Report or Biowaiver (whichever is applicable) within the validity of this CPR in accordance with FDA Circular No. 2016-019. |
| | F | Dangerous Drug - To be prescribed by PDEA S-2 licensed practitioner in a DOH (yellow) prescription form. It is a habit-forming drug. |
| | G | Dangerous Drug - To be prescribed by PDEA S-2 licensed practitioner in a personalized ordinary prescription. It is a habit-forming drug. |
| | H | Patient Information Leaflet - Appropriate information for the consumers shall be written in Filipino and/or local dialects, as appropriate. |
| X | I | Submit a Certificate of Good Manufacturing Practice (GMP) Compliance of Foreign Drug Manufacturer(s) within the validity of this CPR in accordance with A. O. No. 2013-0022 and FDA Circular No. 2014-016. |
| X | J | Review of the submitted Bioequivalence Study Report or Biowaiver, whichever is applicable, shall be completed by the FDA within the validity of this CPR; correspondingly, this CPR shall be revoked if product interchangeability has not been established. |
| | K | Subject to satisfactory compliance to the post-approval commitments detailed in the letter accompanying this CPR. |

REMARKS:

This CPR is granted following A.O. 31 s. 2005.

Exhaustion of all existing inventory of the previous labelling materials is allowed only until **08 October 2020**. No further extension shall be granted.